Pharmaceutical firm GSK opens $130m manufacturing facility in Singapore

The facility is expected to produce anemia and HIV drugs faster.

Multinational pharmaceutical company GlaxoSmithKlyne (GSK) launched two new manufacturing continuous facility and an expanded production building at its Jurong site.

According to GSK, the new and expanded sites will allow the faster production of drugs and Active Pharmaceutical Ingredients (APIs) for clinical trials.

The expansion also reportedly streamlines the manufacturing of APIs which are important for the production of Dolutegravir (Tivicay), a medication used for HIV/AIDS.

Daprodustat, a new oral drug for treating anaemia associated with chronic kidney disease, will reportedly be the first New Chemical Entity to be developed in the facility. GSK expects the new manufacturing process to reduce Daprodustat’s production time.

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.

If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia